Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference The new mini-textbook by Kamps & Hoffmann PDF, 110 pages

Gastric Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 183 articles: HTML format Text format

Single Articles

April 2020
1. ENDO S, Ikenaga M, Yamada T, Tamura S, et al
   Prognostic Factors for Para-aortic Lymph Node Dissection After Neoadjuvant Chemotherapy for Gastric Cancer.
   Anticancer Res. 2020;40:2351-2357.
   PubMed     Text format     Abstract available
   
   
   
2. KATO K, Narita Y, Mitani S, Honda K, et al
   Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer.
   Anticancer Res. 2020;40:2247-2255.
   PubMed     Text format     Abstract available
   
   
   
3. BRAEUER F, Fischer I, Brammen L, Pressl G, et al
   Outcome in Patients Treated With Cytoreductive Surgery and HIPEC for Gastric Cancer With Peritoneal Carcinomatosis.
   Anticancer Res. 2020;40:2151-2156.
   PubMed     Text format     Abstract available
   
   
   
4. KIM HB, Lee HJ, Kim GB, Lim HJ, et al
   Clinical Significance of Jagged-1 Activated by APEX1 as a Chemoresistance Factor in Advanced Gastric Cancer.
   Anticancer Res. 2020;40:1897-1904.
   PubMed     Text format     Abstract available
   
   
   March 2020
5. VIRGILIO E, Proietti A, D'Urso R, Cardelli P, et al
   Elevated Gastric Juice Carbohydrate Antigen 72.4 (Ca 72.4) Is an Independent Prognostic Factor of Poor Survival for Gastric Cancer Patients.
   Anticancer Res. 2020;40:1691-1695.
   PubMed     Text format     Abstract available
   
   
   
6. WATANABE H, Hayashi T, Komori K, Hara K, et al
   Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1.
   Anticancer Res. 2020;40:1683-1690.
   PubMed     Text format     Abstract available
   
   
   
7. HARA K, Aoyama T, Yamada T, Nakazono M, et al
   The Prognostic Value of the Perioperative Systemic Inflammation Score for Patients With Advanced Gastric Cancer.
   Anticancer Res. 2020;40:1503-1512.
   PubMed     Text format     Abstract available
   
   
   
8. MIGITA K, Matsumoto S, Wakatsuki K, Kunishige T, et al
   RNF126 as a Marker of Prognosis and Proliferation of Gastric Cancer.
   Anticancer Res. 2020;40:1367-1374.
   PubMed     Text format     Abstract available
   
   
   February 2020
9. SAWASAKI M, Tsubamoto H, Nakamoto Y, Kakuno A, et al
   S-1, Oxaliplatin, Nab-paclitaxel and Itraconazole for Conversion Surgery for Advanced or Recurrent Gastric Cancer.
   Anticancer Res. 2020;40:991-997.
   PubMed     Text format     Abstract available
   
   
   
10. LEMINI R, Jorgensen MS, Attwood K, Almerey T, et al
    Racial Disparities in Outcomes Among Asians With Gastric Cancer in the USA.
    Anticancer Res. 2020;40:881-889.
    PubMed     Text format     Abstract available
    
    
    
11. FU CK, Chien YC, Chuang HY, Wang YC, et al
    The Association of MMP7 Promoter Polymorphisms With Gastric Cancer.
    Anticancer Res. 2020;40:695-702.
    PubMed     Text format     Abstract available
    
    
    
12. AURELLO P, Cinquepalmi M, Petrucciani N, Moschetta G, et al
    Impact of Anastomotic Leakage on Overall and Disease-free Survival After Surgery for Gastric Carcinoma: A Systematic Review.
    Anticancer Res. 2020;40:619-624.
    PubMed     Text format     Abstract available
    
    
    
13. BAUMGARTNER R, Taghizadeh H, Jomrich G, Schoppmann SF, et al
    Utilization and Efficacy of Palliative Chemotherapy for Locally Advanced or Metastatic Gastroesophageal Carcinoma.
    Anticancer Res. 2020;40:965-975.
    PubMed     Text format     Abstract available
    
    
    January 2020
14. TAMAGAWA H, Aoyama T, Kano K, Numata M, et al
    The Impact of Intraoperative Blood Loss on the Long-term Prognosis after Curative Resection for Borrmann Type IV Gastric Cancer: A Retrospective Multicenter Study.
    Anticancer Res. 2020;40:405-412.
    PubMed     Text format     Abstract available
    
    
    
15. YOO HJ, Kim TJ, Kim DJ, Kim W, et al
    Role of COX2 as a Biomarker for Estimating Survival of Patients With Clinical Stage I Gastric Cancer.
    Anticancer Res. 2020;40:341-347.
    PubMed     Text format     Abstract available
    
    
    
16. ISHIKAWA D, Yoshikawa K, Takasu C, Kashihara H, et al
    Expression Level of MicroRNA-449a Predicts the Prognosis of Patients With Gastric Cancer.
    Anticancer Res. 2020;40:239-244.
    PubMed     Text format     Abstract available
    
    
    
17. TAKANO Y, Shida A, Fujisaki M, Mitsumori N, et al
    Prognostic Significance of ZKSCAN3 (ZNF306) Expression in Gastric Carcinoma.
    Anticancer Res. 2020;40:81-86.
    PubMed     Text format     Abstract available
    
    
    
18. KIJIMA T, Arigami T, Uenosono Y, Hiraki T, et al
    Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer.
    Anticancer Res. 2020;40:75-80.
    PubMed     Text format     Abstract available
    
    
    December 2019
19. BAEK JH, Park DJ, Kim GY, Cheon J, et al
    Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
    Anticancer Res. 2019;39:6973-6979.
    PubMed     Text format     Abstract available
    
    
    
20. KOSUGA T, Konishi T, Kubota T, Shoda K, et al
    Value of Prognostic Nutritional Index as a Predictor of Lymph Node Metastasis in Gastric Cancer.
    Anticancer Res. 2019;39:6843-6849.
    PubMed     Text format     Abstract available
    
    
    
21. YAMAMOTO Y, Kuroda K, Sera T, Sugimoto A, et al
    The Clinicopathological Significance of the CXCR2 Ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in Gastric Cancer.
    Anticancer Res. 2019;39:6645-6652.
    PubMed     Text format     Abstract available
    
    
    
22. ONEYAMA M, Sakamoto N, Oue N, Kimura Y, et al
    Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy.
    Anticancer Res. 2019;39:6567-6573.
    PubMed     Text format     Abstract available
    
    
    
23. KIM JS, Bae GE, Kim KH, Lee SI, et al
    Prognostic Significance of LC3B and p62/SQSTM1 Expression in Gastric Adenocarcinoma.
    Anticancer Res. 2019;39:6711-6722.
    PubMed     Text format     Abstract available
    
    
    November 2019
24. NAEEM B, Ayub A
    Primary Pediatric Non-Hodgkin Lymphomas of the Gastrointestinal Tract: A Population-based Analysis.
    Anticancer Res. 2019;39:6413-6416.
    PubMed     Text format     Abstract available
    
    
    
25. TAKAHASHI Y, Fukuyama T, Futawatari N, Ichiki Y, et al
    Expression of Kita-Kyushu Lung Cancer Antigen-1 as Detected by a Novel Monoclonal Antibody in Gastric Cancer.
    Anticancer Res. 2019;39:6259-6263.
    PubMed     Text format     Abstract available
    
    
    
26. ENDO S, Nishikawa K, Fujitani K, Matsuyama J, et al
    Is D2 Lymphadenectomy Essential for Cytology-positive Gastric Cancer? A Retrospective Analysis.
    Anticancer Res. 2019;39:6209-6216.
    PubMed     Text format     Abstract available
    
    
    
27. SAWAKI K, Kanda M, Umeda S, Miwa T, et al
    Level of Melanotransferrin in Tissue and Sera Serves as a Prognostic Marker of Gastric Cancer.
    Anticancer Res. 2019;39:6125-6133.
    PubMed     Text format     Abstract available
    
    
    
28. NAKATA S, Fujita M, Nakanishi H
    Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells.
    Anticancer Res. 2019;39:5927-5932.
    PubMed     Text format     Abstract available
    
    
    
29. ENDO M, Kanda M, Sawaki K, Shimizu D, et al
    Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer.
    Anticancer Res. 2019;39:5903-5910.
    PubMed     Text format     Abstract available
    
    
    
30. KHING TM, Po WW, Sohn UD
    Fluoxetine Enhances Anti-tumor Activity of Paclitaxel in Gastric Adenocarcinoma Cells by Triggering Apoptosis and Necroptosis.
    Anticancer Res. 2019;39:6155-6163.
    PubMed     Text format     Abstract available
    
    
    October 2019
31. YU JI, Lim DH, Lee J, Kang WK, et al
    Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (</=45 Years) With Gastric Cancer.
    Anticancer Res. 2019;39:5811-5820.
    PubMed     Text format     Abstract available
    
    
    
32. HASHIMOTO I, Sakamaki K, Oue N, Kimura Y, et al
    Clinical Significance of PRKCI Gene Expression in Cancerous Tissue in Patients With Gastric Cancer.
    Anticancer Res. 2019;39:5715-5720.
    PubMed     Text format     Abstract available
    
    
    
33. TSAI KW, Tsai CY, Chou NH, Wang KC, et al
    Aberrant DNA Hypermethylation Silenced LncRNA Expression in Gastric Cancer.
    Anticancer Res. 2019;39:5381-5391.
    PubMed     Text format     Abstract available
    
    
    September 2019
34. ANDO K, Hamada K, Watanabe M, Ohkuma R, et al
    Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors.
    Anticancer Res. 2019;39:5195-5201.
    PubMed     Text format     Abstract available
    
    
    
35. NISHIMURA S, Yashiro M, Sera T, Yamamoto Y, et al
    Feasibility of Identifying Patients at High Risk of Hereditary Gastric Cancer Based on Clinicopathological Variables.
    Anticancer Res. 2019;39:5057-5064.
    PubMed     Text format     Abstract available
    
    
    
36. KUBOTA T, Ichikawa D, Kosuga T, Shoda K, et al
    Does Robotic Distal Gastrectomy Facilitate Minimally Invasive Surgery for Gastric Cancer?
    Anticancer Res. 2019;39:5033-5038.
    PubMed     Text format     Abstract available
    
    
    
37. ITO A, Nakanishi H, Yoshimura M, Ito S, et al
    Dynamics of Circulating Tumor Cells Early After Targeting Therapy to Human EGFR-mutated Lung Cancers and HER2 Gene-amplified Gastric Cancers in Mice.
    Anticancer Res. 2019;39:4711-4720.
    PubMed     Text format     Abstract available
    
    
    
38. WOLL E, Eisterer W, Gerger A, Kuhr T, et al
    Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy.
    Anticancer Res. 2019;39:4589-4596.
    PubMed     Text format     Abstract available
    
    
    August 2019
39. YAMAMOTO K, Hirao M, Nishikawa K, Omori T, et al
    Sarcopenia Is Associated With Impaired Overall Survival After Gastrectomy for Elderly Gastric Cancer.
    Anticancer Res. 2019;39:4297-4303.
    PubMed     Text format     Abstract available
    
    
    
40. NAKAZAWA N, Ogata K, Yokobori T, Ide M, et al
    Low IRBIT Levels Are Associated With Chemo-resistance in Gastric Cancer Patients.
    Anticancer Res. 2019;39:4111-4116.
    PubMed     Text format     Abstract available
    
    
    
41. VIRGILIO E, Giarnieri E, Montagnini M, Villani S, et al
    Advances in Intraluminal Exfoliative Cytology of Gastric Cancer: Oncologic Implication of the Sixth Metastatic Route (Metastasis VI).
    Anticancer Res. 2019;39:4019-4022.
    PubMed     Text format     Abstract available
    
    
    
42. KANG BW, Baek DW, Kang H, Baek JH, et al
    Novel Therapeutic Approaches for Epstein-Barr Virus Associated Gastric Cancer.
    Anticancer Res. 2019;39:4003-4010.
    PubMed     Text format     Abstract available
    
    
    June 2019
43. HIRAHARA N, Tajima Y, Fujii Y, Kaji S, et al
    Comprehensive Analysis of Red Blood Cell Distribution Width as a Preoperative Prognostic Predictor in Gastric Cancer.
    Anticancer Res. 2019;39:3121-3130.
    PubMed     Text format     Abstract available
    
    
    
44. SATO Y, Inokuchi M, Takagi Y, Kojima K, et al
    IGFBP1 Is a Predictive Factor for Haematogenous Metastasis in Patients With Gastric Cancer.
    Anticancer Res. 2019;39:2829-2837.
    PubMed     Text format     Abstract available
    
    
    
45. TAKI T, Hoya Y, Nakada K, Kawamura M, et al
    Gastric Emptying Improved Significantly After PRG Compared to Billroth-I Reconstruction: Assessment of Gastric Emptying With a (13)C-Breath Test.
    Anticancer Res. 2019;39:3227-3230.
    PubMed     Text format     Abstract available
    
    
    May 2019
46. MURAKAMI Y, Saito H, Shimizu S, Kono Y, et al
    Neutrophil-to-Lymphocyte Ratio as a Prognostic Indicator in Patients With Unresectable Gastric Cancer.
    Anticancer Res. 2019;39:2583-2589.
    PubMed     Text format     Abstract available
    
    
    
47. MATSUBARA D, Konishi H, Kubota T, Kosuga T, et al
    Comparison of Clinical Outcomes of Gastrojejunal Bypass and Gastrectomy in Patients With Metastatic Gastric Cancer.
    Anticancer Res. 2019;39:2545-2551.
    PubMed     Text format     Abstract available
    
    
    
48. KUWADA K, Kuroda S, Kikuchi S, Yoshida R, et al
    Clinical Impact of Sarcopenia on Gastric Cancer.
    Anticancer Res. 2019;39:2241-2249.
    PubMed     Text format     Abstract available
    
    
    April 2019
49. YOSHIDA Y, Beppu T, Kinoshita K, Sato N, et al
    Five-year Recurrence-free Survival After Surgery Followed by Oral Chemotherapy for Gastric Cancer With Portal Vein Tumor Thrombosis.
    Anticancer Res. 2019;39:2233-2238.
    PubMed     Text format     Abstract available
    
    
    
50. SEO AN, Kang BW, Bae HI, Kwon OK, et al
    Exon 9 Mutation of PIK3CA Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer.
    Anticancer Res. 2019;39:2145-2154.
    PubMed     Text format     Abstract available
    
    
    
51. LIU JB, Jian T, Yue C, Chen D, et al
    Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus.
    Anticancer Res. 2019;39:1689-1698.
    PubMed     Text format     Abstract available
    
    
    
52. AURELLO P, Berardi G, Moschetta G, Cinquepalmi M, et al
    Recurrence Following Anastomotic Leakage After Surgery for Carcinoma of the Distal Esophagus and Gastroesophageal Junction: A Systematic Review.
    Anticancer Res. 2019;39:1651-1660.
    PubMed     Text format     Abstract available
    
    
    March 2019
53. SAITO R, Kawaguchi Y, Akaike H, Shiraishi K, et al
    Prognostic Significance of Lymph Node Dissection Along the Upper-third-stomach in Patients With Lower-third Gastric Cancer.
    Anticancer Res. 2019;39:1485-1489.
    PubMed     Text format     Abstract available
    
    
    
54. NAKAJI YU, Saeki H, Kudou K, Nakanishi R, et al
    Short- and Long-term Outcomes of Surgical Treatment for Remnant Gastric Cancer After Distal Gastrectomy.
    Anticancer Res. 2019;39:1411-1415.
    PubMed     Text format     Abstract available
    
    
    February 2019
55. AOYAMA T, Yoshikawa T, Maezawa Y, Segami K, et al
    Influence of Postoperative Surgical Complications After Gastrectomy on Body Weight and Body Composition Changes in Patients With Gastric Cancer.
    Anticancer Res. 2019;39:1073-1078.
    PubMed     Text format     Abstract available
    
    
    
56. ENDO S, Kurokawa Y, Gamoh M, Kimura Y, et al
    Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202.
    Anticancer Res. 2019;39:1059-1065.
    PubMed     Text format     Abstract available
    
    
    
57. VIRGILIO E, Giarnieri E, Giovagnoli MR, Montagnini M, et al
    Gastric Lavage Malignant Cells (yGL) and Hypohemoglobinemia (yAnemia) as New Systems of Tumor Regression Grading and Prognostic Prediction for Gastric Cancer After Neoadjuvant Treatment.
    Anticancer Res. 2019;39:1019-1027.
    PubMed     Text format     Abstract available
    
    
    
58. TAMURA T, Sakurai K, Nambara M, Miki Y, et al
    Adverse Effects of Preoperative Sarcopenia on Postoperative Complications of Patients With Gastric Cancer.
    Anticancer Res. 2019;39:987-992.
    PubMed     Text format     Abstract available
    
    
    
59. ELTWERI AM, Thomas AL, Chung WY, Morgan B, et al
    The Effect of Supplementary Omegaven(R) on the Clinical Outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial.
    Anticancer Res. 2019;39:853-861.
    PubMed     Text format     Abstract available
    
    
    January 2019
60. SAITO H, Shimizu S, Kono Y, Murakami Y, et al
    PD-1 Expression on Circulating CD8(+) T-Cells as a Prognostic Marker for Patients With Gastric Cancer.
    Anticancer Res. 2019;39:443-448.
    PubMed     Text format     Abstract available
    
    
    
61. NUMAKURA S, Uozaki H, Kikuchi Y, Watabe S, et al
    Mesenchymal Stem Cell Marker Expression in Gastric Cancer Stroma.
    Anticancer Res. 2019;39:387-393.
    PubMed     Text format     Abstract available
    
    
    
62. BAE GE, Kim HS, Won KY, Kim GY, et al
    Lower Sympathetic Nervous System Density and beta-adrenoreceptor Expression Are Involved in Gastric Cancer Progression.
    Anticancer Res. 2019;39:231-236.
    PubMed     Text format     Abstract available
    
    
    
63. KIM DJ, Kim W
    Lower Esophageal Sphincter-preserving Anastomosis Is an Acceptable Reconstruction Method Following Laparoscopy-assisted Proximal Gastrectomy.
    Anticancer Res. 2019;39:425-430.
    PubMed     Text format     Abstract available
    
    
    December 2018
64. SATO S, Kunisaki C, Tanaka Y, Sato K, et al
    A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer.
    Anticancer Res. 2018;38:6911-6917.
    PubMed     Text format     Abstract available
    
    
    
65. MOCHIZUKI K, Kawai M, Odate T, Tahara I, et al
    SMARCB1/INI1 Is Diagnostically Useful in Distinguishing alpha-Fetoprotein-producing Gastric Carcinoma from Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:6865-6868.
    PubMed     Text format     Abstract available
    
    
    
66. GIATROMANOLAKI A, Koukourakis MI, Georgiou I, Kouroupi M, et al
    LC3A, LC3B and Beclin-1 Expression in Gastric Cancer.
    Anticancer Res. 2018;38:6827-6833.
    PubMed     Text format     Abstract available
    
    
    
67. YANG W, Cai J, Zhang H, Wang G, et al
    Effects of Lidocaine and Ropivacaine on Gastric Cancer Cells Through Down-regulation of ERK1/2 Phosphorylation In Vitro.
    Anticancer Res. 2018;38:6729-6735.
    PubMed     Text format     Abstract available
    
    
    
68. LARBRE V, Alyami M, Mercier F, Vantard N, et al
    No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis.
    Anticancer Res. 2018;38:6869-6875.
    PubMed     Text format     Abstract available
    
    
    November 2018
69. LUCCHETTI J, Formica V, Giuliano G, Coletta D, et al
    Case Report of a Patient with Breast Metastasis from Gastric Cancer Treated with Paclitaxel and Ramucirumab Plus Regional Hyperthermia.
    Anticancer Res. 2018;38:6561-6564.
    PubMed     Text format     Abstract available
    
    
    
70. FUKUCHI M, Mochiki E, Ishiguro T, Kumagai Y, et al
    Prognostic Significance of Conversion Surgery Following First- or Second-line Chemotherapy for Unresectable Gastric Cancer.
    Anticancer Res. 2018;38:6473-6478.
    PubMed     Text format     Abstract available
    
    
    
71. DE FATIMA FERREIRA BORGES DA C, DE Castro Sant' Anna C, Muniz JAPC, DA Rocha CAM, et al
    Deregulation of the SRC Family Tyrosine Kinases in Gastric Carcinogenesis in Non-human Primates.
    Anticancer Res. 2018;38:6317-6320.
    PubMed     Text format     Abstract available
    
    
    
72. SEKINO N, Kano M, Matsumoto Y, Sakata H, et al
    The Antitumor Effects of Metformin on Gastric Cancer In Vitro and on Peritoneal Metastasis.
    Anticancer Res. 2018;38:6263-6269.
    PubMed     Text format     Abstract available
    
    
    
73. KIM HM, Jeong I, Kim HJ, Kang SK, et al
    Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
    Anticancer Res. 2018;38:6171-6180.
    PubMed     Text format     Abstract available
    
    
    
74. MIYOSHI S, Tsugawa H, Matsuzaki J, Hirata K, et al
    Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
    Anticancer Res. 2018;38:6163-6170.
    PubMed     Text format     Abstract available
    
    
    
75. UETA K, Otowa Y, Kakeji Y, Hirashima M, et al
    PROX1 Is Associated with Cancer Progression and Prognosis in Gastric Cancer.
    Anticancer Res. 2018;38:6139-6145.
    PubMed     Text format     Abstract available
    
    
    
76. KAWAKUBO E, Matsumoto T, Yoshiya K, Yamashita S, et al
    BUBR1 Insufficiency Is Correlated with eNOS Reduction Experimentally In Vitro and In Vivo, and in Gastric Cancer Tissue.
    Anticancer Res. 2018;38:6099-6106.
    PubMed     Text format     Abstract available
    
    
    October 2018
77. TANAKA Y, Kunisaki C, Izumisawa Y, Makino H, et al
    A Phase I/II Study of NAC with Docetaxel, Cisplatin, and S-1 for Stage III Gastric Cancer.
    Anticancer Res. 2018;38:6015-6021.
    PubMed     Text format     Abstract available
    
    
    
78. SHINKAI M, Imano M, Chiba Y, Hiraki Y, et al
    Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
    Anticancer Res. 2018;38:5975-5981.
    PubMed     Text format     Abstract available
    
    
    
79. SHINKAI M, Imano M, Chiba Y, Hiraki Y, et al
    Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
    Anticancer Res. 2018;38:5969-5974.
    PubMed     Text format     Abstract available
    
    
    
80. SUGIYAMA K, Narita Y, Mitani S, Honda K, et al
    Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer.
    Anticancer Res. 2018;38:5859-5866.
    PubMed     Text format     Abstract available
    
    
    
81. GONZALEZ-HORMAZABAL P, Romero S, Musleh M, Bustamante M, et al
    IL-8-251T>A (rs4073) Polymorphism Is Associated with Prognosis in Gastric Cancer Patients.
    Anticancer Res. 2018;38:5703-5708.
    PubMed     Text format     Abstract available
    
    
    
82. VIRGILIO E, Ceci D, Cavallini M
    Surgical Endoscopic Vacuum-assisted Closure Therapy (EVAC) in Treating Anastomotic Leakages After Major Resective Surgery of Esophageal and Gastric Cancer.
    Anticancer Res. 2018;38:5581-5587.
    PubMed     Text format     Abstract available
    
    
    
83. ATHAUDA A, Watkins D, Mohammed K, Chau I, et al
    Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
    Anticancer Res. 2018;38:5943-5949.
    PubMed     Text format     Abstract available
    
    
    
84. ISHIGAMI S, Aridome K, Arigami T, Uenosono Y, et al
    Roux-en-Y Plus Distal Jejunal Pouch After Total Gastrectomy: A Prospective Study.
    Anticancer Res. 2018;38:5837-5841.
    PubMed     Text format     Abstract available
    
    
    
85. PARK R, Williamson S, Kasi A, Saeed A, et al
    Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer.
    Anticancer Res. 2018;38:5569-5580.
    PubMed     Text format     Abstract available
    
    
    September 2018
86. KOMATSU S, Kosuga T, Kubota T, Okamoto K, et al
    Preoperative Low Weight Affects Long-term Outcomes Following Curative Gastrectomy for Gastric Cancer.
    Anticancer Res. 2018;38:5331-5337.
    PubMed     Text format     Abstract available
    
    
    
87. ISHIDA R, Kanaji S, Maehara R, Hasegawa H, et al
    Significance of Additional Gastrectomy Including Endoscopic Submucosal Dissection Scar for Gastric Cancer.
    Anticancer Res. 2018;38:5289-5294.
    PubMed     Text format     Abstract available
    
    
    August 2018
88. HIRAHARA N, Tajima Y, Fujii Y, Yamamoto T, et al
    Preoperative Prognostic Nutritional Index Predicts Long-term Outcome in Gastric Cancer: A Propensity Score-matched Analysis.
    Anticancer Res. 2018;38:4735-4746.
    PubMed     Text format     Abstract available
    
    
    
89. HOWARD R, Al Diffalha S, Pimiento J, Mejia J, et al
    CD133 Expression as a Helicobacter pylori-independent Biomarker of Gastric Cancer Progression.
    Anticancer Res. 2018;38:4443-4448.
    PubMed     Text format     Abstract available
    
    
    
90. KASHIHARA H, Shimada M, Yoshikawa K, Higashijima J, et al
    The Effect of Roux-en-Y Reconstruction on Type 2 Diabetes in the Early Postoperative Period.
    Anticancer Res. 2018;38:4901-4905.
    PubMed     Text format     Abstract available
    
    
    July 2018
91. ROMERO S, Musleh M, Bustamante M, Stambuk J, et al
    Polymorphisms in TWIST1 and ZEB1 Are Associated with Prognosis of Gastric Cancer Patients.
    Anticancer Res. 2018;38:3871-3877.
    PubMed     Text format     Abstract available
    
    
    June 2018
92. TANAKA H, Tamura T, Toyokawa T, Muguruma K, et al
    Clinical Relevance of Postoperative Neutrophil-Lymphocyte Ratio (NLR) to Recurrence After Adjuvant Chemotherapy of S-1 for Gastric Cancer.
    Anticancer Res. 2018;38:3745-3751.
    PubMed     Text format     Abstract available
    
    
    
93. OBERMANNOVA R, Redova-Lojova M, Vychytilova-Faltejskova P, Grell P, et al
    Tumor Expression of miR-10b, miR-21, miR-143 and miR-145 Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population.
    Anticancer Res. 2018;38:3719-3724.
    PubMed     Text format     Abstract available
    
    
    
94. MARANO L, Rondelli F, Bartoli A, Testini M, et al
    Oncologic Effectiveness and Safety of Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: Meta-analysis of Randomized Controlled Trials.
    Anticancer Res. 2018;38:3609-3617.
    PubMed     Text format     Abstract available
    
    
    
95. NISHI M, Yoshikawa K, Higashijima J, Tokunaga T, et al
    The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer.
    Anticancer Res. 2018;38:3387-3392.
    PubMed     Text format     Abstract available
    
    
    
96. CHOU NH, Lo YH, Wang KC, Kang CH, et al
    MiR-193a-5p and -3p Play a Distinct Role in Gastric Cancer: miR-193a-3p Suppresses Gastric Cancer Cell Growth by Targeting ETS1 and CCND1.
    Anticancer Res. 2018;38:3309-3318.
    PubMed     Text format     Abstract available
    
    
    
97. BOLM L, Kasmann L, Paysen A, Karapetis C, et al
    Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer.
    Anticancer Res. 2018;38:3231-3242.
    PubMed     Text format     Abstract available
    
    
    
98. CHUNG T, DO SI, Na K, Kim G, et al
    Stromal p16 Overexpression in Gastric-type Mucinous Carcinoma of the Uterine Cervix.
    Anticancer Res. 2018;38:3551-3558.
    PubMed     Text format     Abstract available
    
    
    May 2018
99. HWANG GY, Baek DW, Cho HJ, Lee SJ, et al
    Elevated Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy.
    Anticancer Res. 2018;38:3151-3156.
    PubMed     Text format     Abstract available
    
    
    
100. KIUCHI J, Komatsu S, Kosuga T, Kubota T, et al
     Long-term Postoperative Nutritional Status Affects Prognosis Even After Infectious Complications in Gastric Cancer.
     Anticancer Res. 2018;38:3133-3138.
     PubMed     Text format     Abstract available
     
     
     
101. IWABU J, Namikawa T, Tsuda S, Kitagawa H, et al
     Successful Distal Gastrectomy for Gastric Cancer with Child-Pugh Class B Alcoholic Liver Cirrhosis.
     Anticancer Res. 2018;38:3085-3087.
     PubMed     Text format     Abstract available
     
     
     
102. MARUYAMA S, Furuya S, Shiraishi K, Shimizu H, et al
     Podoplanin Expression as a Prognostic Factor in Gastric Cancer.
     Anticancer Res. 2018;38:2717-2722.
     PubMed     Text format     Abstract available
     
     
     
103. MONDLANE G, Ureba A, Gubanski M, Lind PA, et al
     Estimation of Risk of Normal-tissue Toxicity Following Gastric Cancer Radiotherapy with Photon- or Scanned Proton-beams.
     Anticancer Res. 2018;38:2619-2625.
     PubMed     Text format     Abstract available
     
     
     April 2018
104. OTOWA Y, Suzuki S, Kanaji S, Harada H, et al
     Curative Gastrectomy with Perioperative Chemotherapy Improves the Survival for Unresectable Gastric Cancer.
     Anticancer Res. 2018;38:2363-2368.
     PubMed     Text format     Abstract available
     
     
     
105. HARUTA Y, Nakanishi R, Jogo T, Nakashima Y, et al
     Gastric Cancer of "Crawling Type" Detected by Additional Gastrectomy After Endoscopic Submucosal Resection.
     Anticancer Res. 2018;38:2335-2338.
     PubMed     Text format     Abstract available
     
     
     
106. VIRGILIO E, Balducci G, Mercantini P, Giarnieri E, et al
     Laparoscopic Intragastric Surgery for Treating Early Gastric Cancer.
     Anticancer Res. 2018;38:1911-1916.
     PubMed     Text format     Abstract available
     
     
     
107. CHIU YM, Tsai CL, Kao JT, Hsieh CT, et al
     PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma.
     Anticancer Res. 2018;38:2069-2078.
     PubMed     Text format     Abstract available
     
     
     
108. TSAI CL, Chiu YM, Ho TY, Hsieh CT, et al
     Gallic Acid Induces Apoptosis in Human Gastric Adenocarcinoma Cells.
     Anticancer Res. 2018;38:2057-2067.
     PubMed     Text format     Abstract available
     
     
     March 2018
109. ARATANI K, Sakuramoto S, Chuman M, Kasuya M, et al
     Laparoscopy-assisted Distal Gastrectomy for Gastric Cancer in Elderly Patients: Surgical Outcomes and Prognosis.
     Anticancer Res. 2018;38:1721-1725.
     PubMed     Text format     Abstract available
     
     
     
110. INOKUCHI M, Nakagawa M, Baogok N, Takagi Y, et al
     Prognostic Significance of High EphA1-4 Expression Levels in Locally Advanced Gastric Cancer.
     Anticancer Res. 2018;38:1685-1693.
     PubMed     Text format     Abstract available
     
     
     
111. IGUCHI K, Kunisaki C, Sato S, Tanaka Y, et al
     Evaluation of Optimal Lymph Node Dissection in Remnant Gastric Cancer Based on Initial Distal Gastrectomy.
     Anticancer Res. 2018;38:1677-1683.
     PubMed     Text format     Abstract available
     
     
     
112. KINOSHITA K, Beppu T, Miyata T, Kuramoto K, et al
     A Case of 15-Year Recurrence-free Survival After Microwave Coagulation Therapy for Liver Metastasis from Gastric Cancer.
     Anticancer Res. 2018;38:1595-1598.
     PubMed     Text format     Abstract available
     
     
     
113. HONMA R, Sakamoto N, Ishikawa A, Taniyama D, et al
     Clinicopathological and Prognostic Significance of Epithelial Gremlin1 Expression in Gastric Cancer.
     Anticancer Res. 2018;38:1419-1425.
     PubMed     Text format     Abstract available
     
     
     
114. VIRGILIO E, Giarnieri E, Giovagnoli MR, Montagnini M, et al
     Gastric Cancer Cells in Peritoneal Lavage Fluid: A Systematic Review Comparing Cytological with Molecular Detection for Diagnosis of Peritoneal Metastases and Prediction of Peritoneal Recurrences.
     Anticancer Res. 2018;38:1255-1262.
     PubMed     Text format     Abstract available
     
     
     February 2018
115. PALAJ J, Keckes S, Marek V, Dyttert D, et al
     Fibrinogen Levels Are Associated with Lymph Node Involvement and Overall Survival in Gastric Cancer Patients.
     Anticancer Res. 2018;38:1097-1104.
     PubMed     Text format     Abstract available
     
     
     
116. NAKAMURA A, Matsunaga W, Gotoh A
     Autophagy Induced by Naftopidil Inhibits Apoptosis of Human Gastric Cancer Cells.
     Anticancer Res. 2018;38:803-809.
     PubMed     Text format     Abstract available
     
     
     
117. VIRGILIO E, Giarnieri E, Giovagnoli MR, Montagnini M, et al
     Gastric Juice MicroRNAs as Potential Biomarkers for Screening Gastric Cancer: A Systematic Review.
     Anticancer Res. 2018;38:613-616.
     PubMed     Text format     Abstract available
     
     
     
118. CEAUSU AR, Ciolofan A, Cimpean AM, Magheti A, et al
     The Mesenchymal-Epithelial and Epithelial-Mesenchymal Cellular Plasticity of Liver Metastases with Digestive Origin.
     Anticancer Res. 2018;38:811-816.
     PubMed     Text format     Abstract available
     
     
     January 2018
119. VIRGILIO E, Balducci G, Mercantini P, Giarnieri E, et al
     Utility of Nasogastric Tube for Medical and Surgical Oncology of Gastric Cancer: A Prospective Institutional Study on a New and Precious Application of an Old and Economic Device.
     Anticancer Res. 2018;38:433-439.
     PubMed     Text format     Abstract available
     
     
     
120. SHIN SH, Park SS, Ju EJ, Park J, et al
     Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer.
     Anticancer Res. 2018;38:287-293.
     PubMed     Text format     Abstract available
     
     
     
121. SAITO H, Kono Y, Murakami Y, Shishido Y, et al
     Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.
     Anticancer Res. 2018;38:107-112.
     PubMed     Text format     Abstract available
     
     
     
122. DOMINGUEZ C, Rosa M, George TB, Pimiento J, et al
     Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
     Anticancer Res. 2018;38:367-372.
     PubMed     Text format     Abstract available
     
     
     December 2017
123. MASUISHI T, Kadowaki S, Kondo M, Komori A, et al
     FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis.
     Anticancer Res. 2017;37:7037-7042.
     PubMed     Text format     Abstract available
     
     
     
124. FUJII H, Iihara H, Kajikawa N, Kobayashi R, et al
     Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy.
     Anticancer Res. 2017;37:6831-6837.
     PubMed     Text format     Abstract available
     
     
     
125. INOKUCHI M, Higuchi K, Takagi Y, Tanioka T, et al
     Cadherin 5 Is a Significant Risk Factor for Hematogenous Recurrence and a Prognostic Factor in Locally Advanced Gastric Cancer.
     Anticancer Res. 2017;37:6807-6813.
     PubMed     Text format     Abstract available
     
     
     
126. NISHI M, Batsaikhan BE, Yoshikawa K, Higashijima J, et al
     High STAT4 Expression Indicates Better Disease-free Survival in Patients with Gastric Cancer.
     Anticancer Res. 2017;37:6723-6729.
     PubMed     Text format     Abstract available
     
     
     
127. ANDREOU A, Pesthy S, Struecker B, Dadras M, et al
     Incidence and Risk Factors of Symptomatic Hiatal Hernia Following Resection for Gastric and Esophageal Cancer.
     Anticancer Res. 2017;37:7031-7036.
     PubMed     Text format     Abstract available
     
     
     November 2017
128. KANAZAWA Y, Yamada T, Fujita I, Kakinuma D, et al
     In Vitro Chemosensitivity Test for Gastric Cancer Specimens Predicts Effectiveness of Oxaliplatin and 5-Fluorouracil.
     Anticancer Res. 2017;37:6401-6405.
     PubMed     Text format     Abstract available
     
     
     October 2017
129. VIRGILIO E, Balducci G, Mercantini P, Ferri M, et al
     Reconstruction After Distal Gastrectomy for Gastric Cancer: Billroth 2 or Roux-En-Y Procedure?
     Anticancer Res. 2017;37:5595-5602.
     PubMed     Text format     Abstract available
     
     
     
130. WOLL E, Thaler J, Keil F, Gruenberger B, et al
     Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.
     Anticancer Res. 2017;37:5553-5558.
     PubMed     Text format     Abstract available
     
     
     
131. LEE AA, Poddar N, Hammami MB, Veerapong J, et al
     Gastric Spindle Cell Neuroendocrine Tumor Mimicking Gastrointestinal Stromal Tumor: Unique Morphology and Diagnostic Pitfall.
     Anticancer Res. 2017;37:5893-5897.
     PubMed     Text format     Abstract available
     
     
     September 2017
132. PACHNIA D, Drop B, Dworzanska A, Kliszczewska E, et al
     Transforming Growth Factor-beta, Interleukin-10, and Serological Markers in EBV-associated Gastric Carcinoma.
     Anticancer Res. 2017;37:4853-4858.
     PubMed     Text format     Abstract available
     
     
     August 2017
133. YIN J, Song JN, Bai ZG, Cai J, et al
     Gastric Cancer Mortality Trends in China (2006-2013) Reveal Increasing Mortality in Young Subjects.
     Anticancer Res. 2017;37:4671-4679.
     PubMed     Text format     Abstract available
     
     
     
134. DONG W, Li B, Wang J, Song Y, et al
     Exploration of the Radiotherapeutic Clinical Target Volume Delineation for Gastric Cancer from Lymph Node Metastases.
     Anticancer Res. 2017;37:4629-4634.
     PubMed     Text format     Abstract available
     
     
     
135. HUO X, Xiao X, Zhang S, Zhou D, et al
     Association of Intron Microsatellite Instability and Exon Mutational Profile of TP53 in Human Gastric Cancers.
     Anticancer Res. 2017;37:4507-4514.
     PubMed     Text format     Abstract available
     
     
     
136. YIN J, Cui Y, Li L, Ji J, et al
     Overexpression of EPHB4 Is Associated with Poor Survival of Patients with Gastric Cancer.
     Anticancer Res. 2017;37:4489-4497.
     PubMed     Text format     Abstract available
     
     
     
137. LI L, Cui Y, Ji JF, Jiang WG, et al
     Clinical Correlation Between WISP2 and beta-Catenin in Gastric Cancer.
     Anticancer Res. 2017;37:4469-4473.
     PubMed     Text format     Abstract available
     
     
     
138. JIANG A, Zhao H, Liu X, Yu M, et al
     Comparison of Different Muscle-Relaxant Anesthetics on Growth, Migration and Invasion of Gastric Cancer Cells.
     Anticancer Res. 2017;37:4371-4378.
     PubMed     Text format     Abstract available
     
     
     
139. MIMATSU K, Fukino N, Ogasawara Y, Saino Y, et al
     Utility of Inflammatory Marker- and Nutritional Status-based Prognostic Factors for Predicting the Prognosis of Stage IV Gastric Cancer Patients Undergoing Non-curative Surgery.
     Anticancer Res. 2017;37:4215-4222.
     PubMed     Text format     Abstract available
     
     
     
140. VIRGILIO E, Giarnieri E, Giovagnoli MR, Montagnini M, et al
     Early Gastric Cancer Exfoliating into Gastric Lavage (GL1 EGC) Shows a More Aggressive Behavior and Poorer Survival Compared to the Non-Exfoliative Counterpart (GL0 EGC).
     Anticancer Res. 2017;37:4199-4203.
     PubMed     Text format     Abstract available
     
     
     
141. LIU L, Zhao H, Sheng L, Yang P, et al
     Collision of Lymphoepithelioma-like Carcinoma with Diffuse Large B-cell Lymphoma of the Stomach: A Case Report.
     Anticancer Res. 2017;37:4569-4573.
     PubMed     Text format     Abstract available
     
     
     
142. GONG Z, Mu Y, Chen J, Chu H, et al
     Expression and Significance of Cyclophilin J in Primary Gastric Adenocarcinoma.
     Anticancer Res. 2017;37:4475-4481.
     PubMed     Text format     Abstract available
     
     
     July 2017
143. TAKIMOTO R, Kamigaki T, Okada S, Matsuda E, et al
     Efficacy of Adoptive Immune-cell Therapy in Patients with Advanced Gastric Cancer: A Retrospective Study.
     Anticancer Res. 2017;37:3947-3954.
     PubMed     Text format     Abstract available
     
     
     
144. SATAKE H, Kondo M, Mizumoto M, Kotake T, et al
     Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer.
     Anticancer Res. 2017;37:3703-3710.
     PubMed     Text format     Abstract available
     
     
     
145. KAITO A, Kinoshita T, Tokunaga M, Sunagawa H, et al
     Prognostic Factors and Recurrence Pattern of Far-advanced Gastric Cancer with Pathologically-positive Para-aortic Lymph Nodes.
     Anticancer Res. 2017;37:3685-3692.
     PubMed     Text format     Abstract available
     
     
     
146. KASHIHARA H, Shimada M, Yoshikawa K, Higashijima J, et al
     Correlation Between Thrombospondin-1 Expression in Non-cancer Tissue and Gastric Carcinogenesis.
     Anticancer Res. 2017;37:3547-3552.
     PubMed     Text format     Abstract available
     
     
     June 2017
147. MOON JH, Fujiwara Y, Hirao M, Imamura H, et al
     Randomized Controlled Trial of Adjuvant Chemotherapy with Fluoropyrimidines Versus Surgery-alone for Gastric Cancer.
     Anticancer Res. 2017;37:3061-3067.
     PubMed     Text format     Abstract available
     
     
     
148. TOKUMOTO M, Tanaka H, Tauchi Y, Tamura T, et al
     Immunoregulatory Function of Lymphatic Endothelial Cells in Tumor-draining Lymph Nodes of Human Gastric Cancer.
     Anticancer Res. 2017;37:2875-2883.
     PubMed     Text format     Abstract available
     
     
     
149. VIRGILIO E, Proietti A, D'Urso R, Cardelli P, et al
     Measuring Intragastric Tumor Markers in Gastric Cancer Patients: a Systematic Literature Review on Significance and Reliability.
     Anticancer Res. 2017;37:2817-2821.
     PubMed     Text format     Abstract available
     
     
     
150. ARATANI K, Komatsu S, Ichikawa D, Ohashi T, et al
     Overexpression of EGFR as an Independent Prognostic Factor in Adenocarcinoma of the Esophagogastric Junction.
     Anticancer Res. 2017;37:3129-3135.
     PubMed     Text format     Abstract available
     
     
     May 2017
151. KANAZAWA Y, Fujita I, Kakinuma D, Arai H, et al
     Initial Experience with Nab-Paclitaxel for Patients with Advanced Gastric Cancer: Safety and Efficacy.
     Anticancer Res. 2017;37:2715-2720.
     PubMed     Text format     Abstract available
     
     
     
152. INADOMI K, Kusaba H, Matsushita Y, Tanaka R, et al
     Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer.
     Anticancer Res. 2017;37:2663-2671.
     PubMed     Text format     Abstract available
     
     
     
153. DA SILVA OLIVEIRA KC, Bona AB, DA Silva FJ, Pinheiro TM, et al
     Expression of hsa-miR-9 and MYC Copy Number Variation in Hereditary Diffuse Gastric Cancer.
     Anticancer Res. 2017;37:2401-2406.
     PubMed     Text format     Abstract available
     
     
     April 2017
154. TAHARA T, Tahara S, Horiguchi N, Kawamura T, et al
     Telomere Length in Leukocyte DNA in Gastric Cancer Patients and its Association with Clinicopathological Features and Prognosis.
     Anticancer Res. 2017;37:1997-2001.
     PubMed     Text format     Abstract available
     
     
     
155. KUNIZAKI M, Fukuda A, Wakata K, Tominaga T, et al
     Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
     Anticancer Res. 2017;37:1979-1984.
     PubMed     Text format     Abstract available
     
     
     March 2017
156. FUKUCHI M, Mochiki E, Ishiguro T, Ogura T, et al
     Efficacy of Conversion Surgery Following S-1 plus Cisplatin or Oxaliplatin Chemotherapy for Unresectable Gastric Cancer.
     Anticancer Res. 2017;37:1343-1347.
     PubMed     Text format     Abstract available
     
     
     
157. MITA K, Ito H, Ota E, Takahashi K, et al
     Adjuvant Chemotherapy with S-1 plus Cisplatin for Patients with Stage III Gastric Cancer After Curative Resection.
     Anticancer Res. 2017;37:1329-1333.
     PubMed     Text format     Abstract available
     
     
     
158. AHN SY, Kim J, Kim MA, Choi J, et al
     Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
     Anticancer Res. 2017;37:1127-1138.
     PubMed     Text format     Abstract available
     
     
     
159. DAI X, Liu D, Liu M, Zhang X, et al
     Anti-metastatic Efficacy of Traditional Chinese Medicine (TCM) Ginsenoside Conjugated to a VEFGR-3 Antibody on Human Gastric Cancer in an Orthotopic Mouse Model.
     Anticancer Res. 2017;37:979-986.
     PubMed     Text format     Abstract available
     
     
     February 2017
160. SATOH T, Kaira K, Takahashi K, Takahashi N, et al
     Prognostic Significance of the Expression of CD98 (4F2hc) in Gastric Cancer.
     Anticancer Res. 2017;37:631-636.
     PubMed     Text format     Abstract available
     
     
     
161. BAUER G
     Central Signaling Elements of Intercellular Reactive Oxygen/Nitrogen Species-dependent Induction of Apoptosis in Malignant Cells.
     Anticancer Res. 2017;37:499-513.
     PubMed     Text format     Abstract available
     
     
     
162. BACKMAN S, Norlen O, Eriksson B, Skogseid B, et al
     Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
     Anticancer Res. 2017;37:705-712.
     PubMed     Text format     Abstract available
     
     
     
163. PROUET P, Giri S, Wiedower E, Fintel A, et al
     Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality.
     Anticancer Res. 2017;37:813-817.
     PubMed     Text format     Abstract available
     
     
     January 2017
164. OGATA K, Yanai M, Kuriyama K, Suzuki M, et al
     Double Endoscopic Intraluminal Operation (DEILO) for Early Gastric Cancer: Outcome of Novel Procedure for Endoscopic Submucosal Dissection.
     Anticancer Res. 2017;37:343-347.
     PubMed     Text format     Abstract available
     
     
     
165. SUGIYAMA K, Narita Y, Kadowaki S, Ura T, et al
     Platinum-based Doublet Chemotherapy for Advanced Gastric Cancer with Disseminated Intravascular Coagulation.
     Anticancer Res. 2017;37:309-313.
     PubMed     Text format     Abstract available
     
     
     
166. JUKIC Z, Radulovic P, Stojkovic R, Mijic A, et al
     Gender Difference in Distribution of Estrogen and Androgen Receptors in Intestinal-type Gastric Cancer.
     Anticancer Res. 2017;37:197-202.
     PubMed     Text format     Abstract available
     
     
     
167. KOGURE N, Yokobori T, Ogata K, Altan B, et al
     Low Expression of FBXO45 Is Associated with Gastric Cancer Progression and Poor Prognosis.
     Anticancer Res. 2017;37:191-196.
     PubMed     Text format     Abstract available
     
     
     
168. LEE D, Yu EJ, Ham IH, Hur H, et al
     Clinicopathological Implication of Insulin-like Growth Factor-II mRNA-Binding Protein 3 (IMP3) Expression in Gastric Cancer.
     Anticancer Res. 2017;37:135-142.
     PubMed     Text format     Abstract available
     
     
     December 2016
169. FUKUCHI M, Mochiki E, Ishiguro T, Ogura T, et al
     Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer.
     Anticancer Res. 2016;36:6699-6703.
     PubMed     Text format     Abstract available
     
     
     
170. TOIYAMA Y, Shimura T, Yasuda H, Fujikawa H, et al
     Clinical Burden of C-Reactive Protein/Albumin Ratio Before Curative Surgery for Patients with Gastric Cancer.
     Anticancer Res. 2016;36:6491-6498.
     PubMed     Text format     Abstract available
     
     
     November 2016
171. ZHENG LC, Yang MD, Kuo CL, Lin CH, et al
     Norcantharidin-induced Apoptosis of AGS Human Gastric Cancer Cells Through Reactive Oxygen Species Production, and Caspase- and Mitochondria-dependent Signaling Pathways.
     Anticancer Res. 2016;36:6031-6042.
     PubMed     Text format     Abstract available
     
     
     
172. HAYASHI N, Kataoka H, Yano S, Kikuchi JI, et al
     Anticancer Effects of a New Aminosugar-conjugated Platinum Complex Agent Against Cisplatin-resistant Gastric Cancer.
     Anticancer Res. 2016;36:6005-6009.
     PubMed     Text format     Abstract available
     
     
     October 2016
173. ARIGAMI T, Uenosono Y, Ishigami S, Yanagita S, et al
     Clinical Impact of Stomach-partitioning Gastrojejunostomy with Braun Enteroenterostomy for Patients with Gastric Outlet Obstruction Caused by Unresectable Gastric Cancer.
     Anticancer Res. 2016;36:5431-5436.
     PubMed     Text format     Abstract available
     
     
     
174. ALTAN B, Yokobori T, Ide M, Bai T, et al
     High Expression of MRE11-RAD50-NBS1 Is Associated with Poor Prognosis and Chemoresistance in Gastric Cancer.
     Anticancer Res. 2016;36:5237-5247.
     PubMed     Text format     Abstract available
     
     
     
175. YAWATA K, Osada S, Tanahashi T, Matsui S, et al
     The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.
     Anticancer Res. 2016;36:5215-5226.
     PubMed     Text format     Abstract available
     
     
     
176. LEMOINE N, Adenis A, Bouche O, Duhamel A, et al
     Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma.
     Anticancer Res. 2016;36:5543-5549.
     PubMed     Text format     Abstract available
     
     
     
177. KNIEF J, Reddemann K, Petrova E, Herhahn T, et al
     High Density of Tumor-infiltrating B-Lymphocytes and Plasma Cells Signifies Prolonged Overall Survival in Adenocarcinoma of the Esophagogastric Junction.
     Anticancer Res. 2016;36:5339-5345.
     PubMed     Text format     Abstract available
     
     
     September 2016
178. KIM EY, Jun KH, Jung JH, Jo YS, et al
     Laparoscopic Gastrectomy Followed by Chemotherapy for Advanced Gastric Cancer Diagnosed During Pregnancy: A Case Report.
     Anticancer Res. 2016;36:4813-6.
     PubMed     Text format     Abstract available
     
     
     
179. KIM DJ, Kim W
     Laparoscopy-assisted Proximal Gastrectomy with Double Tract Anastomosis Is Beneficial for Vitamin B12 and Iron Absorption.
     Anticancer Res. 2016;36:4753-8.
     PubMed     Text format     Abstract available
     
     
     August 2016
180. ROMAN LD, Lukyanchuk R, Sablin OA, Araslanova EI, et al
     Prevalence of H. pylori Infection and Atrophic Gastritis in a Population-based Screening with Serum Biomarker Panel (GastroPanel(R)) in St. Petersburg.
     Anticancer Res. 2016;36:4129-38.
     PubMed     Text format     Abstract available
     
     
     June 2016
181. KOMATSU S, Ichikawa D, Kosuga T, Okamoto K, et al
     Clinical Impact of Laparoscopy and Endoscopy Cooperative Surgery (LECS) on Gastric Submucosal Tumor After its Standardization.
     Anticancer Res. 2016;36:3041-7.
     PubMed     Text format     Abstract available
     
     
     
182. YONENAGA Y, Kurosawa M, Mise M, Yamagishi M, et al
     Pancreatic-type Acinar Cell Carcinoma of the Stomach Included in Multiple Primary Carcinomas.
     Anticancer Res. 2016;36:2855-64.
     PubMed     Text format     Abstract available
     
     
     March 2016
183. ZIMMERMANN N, Lazar-Karsten P, Keck T, Billmann F, et al
     Expression Pattern of CDX2, Estrogen and Progesterone Receptors in Primary Gastroenteropancreatic Neuroendocrine Tumors and Metastases.
     Anticancer Res. 2016;36:921-4.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: